Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

CryptoAlerta — análise de criptomoedas e mercado em tempo real